Evaluation of the HBV liver reservoir with fine needle aspirates.
FNA
HBV
Liver biopsy
cccDNA
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
21
04
2023
revised:
19
06
2023
accepted:
22
06
2023
medline:
7
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
Finite duration of treatment associated with HBsAg loss is the current goal for improved therapeutic approaches against chronic HBV infection, as it indicates elimination or durable inactivation of intrahepatic covalently closed circular DNA (cccDNA). To assist drug development, the definition of early predictive markers of HBsAg loss by assessing their value in reflecting intrahepatic cccDNA levels and transcriptional activity is essential. Fine needle aspirates (FNAs) have recently emerged as a less invasive alternative to core liver biopsy (CLB) and showed to be useful for investigating intrahepatic immune responses. The aim of this study was to optimise and validate the use of FNA Paired FNA/CLB samples were obtained from patients with HBeAg+ chronic hepatitis (n = 4), HBeAg- chronic hepatitis (n = 4), and HBeAg- chronic infection (n = 1). One HBeAg+ patient was undergoing tenofovir treatment. HBV 3.5-kb RNA and cccDNA were quantified by droplet digital PCR. cccDNA was quantifiable in all but one FNA/CLB pair, showing the highest levels in untreated HBeAg+ patients, except for the tenofovir-treated patient. Similarly, 3.5-kb RNA was detectable in all but one FNA sample and showed higher levels in HBeAg+ patients. When comparing cccDNA and 3.5-kb RNA quantification in FNA These results demonstrate the possibility to quantify cccDNA and assess its transcriptional activity in patients with chronic hepatitis B by combining FNA and droplet digital PCR. This supports the use of FNA in clinical trials to evaluate the intrahepatic viral reservoir during the development of new antivirals and immunomodulatory agents. Chronic hepatitis B infection is characterised by a complex interplay between immune responses and viral replication in the liver, which determines the long-term outcome of the disease. In this study, we show that fine needle aspiration of the liver, a less-invasive alternative to core biopsies, allows the assessment of the hepatic viral reservoir.
Sections du résumé
Background & Aims
UNASSIGNED
Finite duration of treatment associated with HBsAg loss is the current goal for improved therapeutic approaches against chronic HBV infection, as it indicates elimination or durable inactivation of intrahepatic covalently closed circular DNA (cccDNA). To assist drug development, the definition of early predictive markers of HBsAg loss by assessing their value in reflecting intrahepatic cccDNA levels and transcriptional activity is essential. Fine needle aspirates (FNAs) have recently emerged as a less invasive alternative to core liver biopsy (CLB) and showed to be useful for investigating intrahepatic immune responses. The aim of this study was to optimise and validate the use of FNA
Methods
UNASSIGNED
Paired FNA/CLB samples were obtained from patients with HBeAg+ chronic hepatitis (n = 4), HBeAg- chronic hepatitis (n = 4), and HBeAg- chronic infection (n = 1). One HBeAg+ patient was undergoing tenofovir treatment. HBV 3.5-kb RNA and cccDNA were quantified by droplet digital PCR.
Results
UNASSIGNED
cccDNA was quantifiable in all but one FNA/CLB pair, showing the highest levels in untreated HBeAg+ patients, except for the tenofovir-treated patient. Similarly, 3.5-kb RNA was detectable in all but one FNA sample and showed higher levels in HBeAg+ patients. When comparing cccDNA and 3.5-kb RNA quantification in FNA
Conclusions
UNASSIGNED
These results demonstrate the possibility to quantify cccDNA and assess its transcriptional activity in patients with chronic hepatitis B by combining FNA and droplet digital PCR. This supports the use of FNA in clinical trials to evaluate the intrahepatic viral reservoir during the development of new antivirals and immunomodulatory agents.
Impact and implications
UNASSIGNED
Chronic hepatitis B infection is characterised by a complex interplay between immune responses and viral replication in the liver, which determines the long-term outcome of the disease. In this study, we show that fine needle aspiration of the liver, a less-invasive alternative to core biopsies, allows the assessment of the hepatic viral reservoir.
Identifiants
pubmed: 37675272
doi: 10.1016/j.jhepr.2023.100841
pii: S2589-5559(23)00172-6
pmc: PMC10477677
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100841Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
FZ received grants from Assembly, Beam Therapeutics, and Evotec; FZ had consulting activities with Assembly, Blue Jay, Gilead, and GSK. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
J Clin Virol. 2022 Jun;150-151:105150
pubmed: 35427860
JHEP Rep. 2023 Mar 10;5(6):100728
pubmed: 37122357
Gut. 2014 Mar;63(3):515-24
pubmed: 23665989
Gut. 2019 Aug;68(8):1493-1503
pubmed: 30487267
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
J Hepatol. 2021 Apr;74(4):794-800
pubmed: 33188905
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
Gut. 2023 May;72(5):972-983
pubmed: 36707234
J Clin Invest. 2023 Jan 3;133(1):
pubmed: 36594467
J Hepatol. 2021 Sep;75(3):706-717
pubmed: 34051332
J Hepatol. 2023 Mar 25;:
pubmed: 36972796
Sci Rep. 2020 Dec 3;10(1):21097
pubmed: 33273565
Liver Int. 2021 Jun;41 Suppl 1:15-23
pubmed: 34155787
JHEP Rep. 2022 Apr 02;4(6):100480
pubmed: 35493765
J Hepatol. 2018 Aug;69(2):301-307
pubmed: 29621551
JCI Insight. 2020 Oct 2;5(19):
pubmed: 33004689
Gut. 2018 Apr;67(4):767-775
pubmed: 29331944